Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.22.2.2
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized         $ 3,891,000 $ 5,697,000 $ 15,634,000 $ 15,686,000    
Deferred revenue         1,625,000   1,625,000   $ 10,181,000  
Global Blood Therapeutics                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue         1,585,000   1,585,000   8,913,000  
Global Blood Therapeutics | Collaboration Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Initial period of research term 3 years                  
Additional extension period for research term upon mutual agreement 1 year                  
Upfront payment receivable $ 20,000,000.0                  
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0                  
Agreement termination, prior written notice if notice delivered during the research term 90 days                  
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 9 months                  
Total transaction price $ 60,000,000.0           49,300,000   54,200,000 $ 60,000,000.0
Upfront non-refundable and non-creditable payment 20,000,000.0                  
Reimbursable costs $ 40,000,000.0                  
Revenue recognized         3,700,000 5,600,000 14,400,000 12,900,000    
Deferred revenue         1,600,000   1,600,000      
Global Blood Therapeutics | Collaboration Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Period of extension of initial research term 2 years                  
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0                  
Incyte                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized         200,000 $ 100,000 1,200,000 $ 2,800,000    
Deferred revenue         $ 40,000.0   40,000.0   $ 1,268,000  
Incyte | Stock Purchase Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Aggregate purchase price       $ 10,000,000.0            
Shares issued       793,021            
Share price (in dollars per share)       $ 12.61            
Premium to volume-weighted sale price of shares (as a percent)       30.00%            
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days            
Incyte | Collaboration Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total transaction price   $ 12,300,000 $ 12,800,000       12,800,000      
Upfront non-refundable and non-creditable payment             2,500,000      
Up-front consideration       $ 10,000,000.0            
Up-front consideration, cash       2,500,000            
Up-front consideration, pre-paid research funding       $ 7,500,000            
Prepaid research amount             7,500,000      
Premium paid on equity investment             2,300,000      
Collaboration agreement additional consideration incurred             $ 500,000